<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Rising population age and advances in treatment with improved survival from <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> have led to more frequent survivors of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> treatment and subsequently to more patients with a second <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumour</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The consequences are presented in this overview </plain></SENT>
<SENT sid="2" pm="."><plain>METHOD: For the literature review, the Medline database (PubMed) was searched under the key words "multiple primary <z:mp ids='MP_0002018'>malignant tumors</z:mp>" and "(<z:hpo ids='HP_0002664'>Neoplasms</z:hpo>, second primary) AND "<z:hpo ids='HP_0002664'>Neoplasms</z:hpo>, Second Primary"[Mesh]" </plain></SENT>
<SENT sid="3" pm="."><plain>Primarily, publications in the last 7 years (2005 - 2011) were sought </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: The prevalence of patients with <z:e sem="disease" ids="C0751623" disease_type="Neoplastic Process" abbrv="">second primary cancer</z:e> is reported in various <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> registries with 6.6 % to 9 % </plain></SENT>
<SENT sid="5" pm="."><plain>Here, the risk of developing new primary <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> survivors, depending on age, compared to the general population is increased at least by 20 % </plain></SENT>
<SENT sid="6" pm="."><plain>Among <z:e sem="disease" ids="C0278704" disease_type="Neoplastic Process" abbrv="">childhood cancer</z:e> survivors, the risk was even 3 - to 6-times higher than would have been expected in the general population </plain></SENT>
<SENT sid="7" pm="."><plain>The incidence of second malignant <z:hpo ids='HP_0002664'>neoplasms</z:hpo> is crucially dependent on the prognosis of the first <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Fifteen years after initial diagnosis, in patients with prognostically unfavourable <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> such as pancreatic or gastric <z:mp ids='MP_0002038'>carcinoma</z:mp>, <z:e sem="disease" ids="C0751623" disease_type="Neoplastic Process" abbrv="">second primary malignancies</z:e> are detected in less than 5 % </plain></SENT>
<SENT sid="9" pm="."><plain>However, the cumulative incidence of <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C0751623" disease_type="Neoplastic Process" abbrv="">second cancers</z:e> combined is approximately 15 % at 25 years in patients with colorectal or <z:e sem="disease" ids="C0007115" disease_type="Neoplastic Process" abbrv="">thyroid cancer</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: Implications from these data arise for primary diagnostics which must look at <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> with frequent synchronous <z:e sem="disease" ids="C0085183" disease_type="Neoplastic Process" abbrv="">second malignancies</z:e> for respective <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> before treatment </plain></SENT>
<SENT sid="11" pm="."><plain>Examples are synchronous colorectal lesions in patients with colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> or synchronous <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> of the oral cavity and pharynx in patients with oesophageal <z:mp ids='MP_0002038'>carcinoma</z:mp> </plain></SENT>
<SENT sid="12" pm="."><plain>Another consequence is a targeted follow-up of corresponding risk populations </plain></SENT>
<SENT sid="13" pm="."><plain>This includes the screening for metachronous <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, the exclusion of gastrointestinal <z:e sem="disease" ids="C0085183" disease_type="Neoplastic Process" abbrv="">second malignancies</z:e> in patients with <z:hpo ids='HP_0100723'>GIST</z:hpo>, or the <z:hpo ids='HP_0003002'>breast cancer</z:hpo> screening in young female <z:e sem="disease" ids="C0007115" disease_type="Neoplastic Process" abbrv="">thyroid cancer</z:e> survivors </plain></SENT>
<SENT sid="14" pm="."><plain>Since radiotherapy increases the rate of second primary <z:hpo ids='HP_0002664'>neoplasms</z:hpo>, adjuvant radiotherapy should be well justified </plain></SENT>
<SENT sid="15" pm="."><plain>Nevertheless, this is true only for young patients, mainly in childhood </plain></SENT>
<SENT sid="16" pm="."><plain>The risk of a <z:e sem="disease" ids="C0751623" disease_type="Neoplastic Process" abbrv="">second cancer</z:e> after irradiation in adults is small </plain></SENT>
</text></document>